RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its wholly owned subsidiary, ADMA BioCenters in Norcross, Georgia, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea.
“We are very pleased to receive Korean MFDS approval for our plasma collection facility,” stated Adam Grossman, President and Chief Executive Officer of ADMA. “This approval further enhances our existing global presence as a source plasma provider, which includes the U.S., Europe and now South Korea. This regulatory milestone is a result of ADMA’s commitment to quality and adherence to the regulatory requirements of the global plasma community.”
Help employers find you! Check out all the jobs and post your resume.
